Abstract
Introduction

30
Streptococcus pyogenes (group A streptococcus, GAS) is a human pathogen causing a 31 diverse range of diseases. GAS can cause mild infections such as tonsillitis and impetigo but 32 also severe diseases such as streptococcal toxic shock syndrome, necrotizing fasciitis, and 33 erysipelas 1 . Furthermore, repeated and/or untreated GAS infections can trigger serious 34 postinfectious immune-mediated disorders, including acute poststreptococcal 35 glomerulonephritis, acute rheumatic fever, and rheumatic heart disease 1 . With a prevalence of 36 at least 18 million severe cases, leading to approximately half a million deaths world wide 37 annually as well as over 700 million annual cases of mild infections 2 , GAS infections are a 38 large public health burden. 39
Protective immunity towards GAS is generally poor and recurrent infections are not 40 uncommon, especially in children 3 . This is despite the fact that most people do in fact raise 41 an adaptive immune response and exhibit high titers of IgG antibodies towards different GAS 42 antigens [4] [5] [6] [7] . The reason for the lack of protection is not entirely understood but can in part be 43 attributed to the large number of different GAS serotypes and the surface antigen variability 44 this entails 8 . GAS is also able to counteract adaptive immunity by specifically impairing IgG 45 function. This can be mediated by non-immune IgG binding to Fc binding proteins on the 46 streptococcal surface such as the M and M-related proteins 9,10 or through specific degradation 47 of the IgGs themselves. GAS secretes for example the IgG specific protease IdeS which is 48 able to cleave the antibody in the hinge region, separating the antigen-binding Fabs from the 49 effector function-promoting Fc region 11 . 50 GAS is further able to degrade IgGs by secretion of the endoglycosidase EndoS. This enzyme 51 cleaves the conserved Fc N-glycan from IgGs with great specificity 12 (Fig. 1a) . This glycan is 52 situated at the interaction surface between the IgG and Fc receptors 13, 14 as well as the 53 complement system 15 and is therefore ideally located to influence IgG effector function. 54
While an antibody´s specificity is determined by the Fab regions, the Fc region determines 55 which effector functions are elicited and the structure of the Fc glycan has been shown to be 56 crucial in the regulation of this process 16 . For example, IgGs lacking core fucosylation exhibit 57 increased affinity for FcγRIIIA and are therefore significantly more potent in eliciting 58 antibody-dependent cellular cytotoxicity 17, 18 . Furthermore, the degree of galactosylation of 59 the Fc glycan influences an IgGs ability to activate the complement system 19 . Consequently, 60
IgG antibodies lacking the Fc glycan fail to bind to most Fc receptors and are unable to 61 activate the complement system 20, 21 . Despite the accumulating evidence that antibody glycans 62 are instrumental in regulating and fine tuning the immune response, very little is know about 63 the role of antibody glycosylation during infections and if it contributes to the outcome of 64 disease. However, recent high profile studies that have suggested that the IgG glycosylation 65 status influences whether HIV infection is controlled 22, 24 and whether Mycobacterium 66 tuberculosis infection is active or latent 23 . 67
Due to this functional importance of the Fc N-glycan, its hydrolysis by EndoS leads to 68 impaired IgG effector functions such as Fc receptor binding and complement activation in 69 vitro 20, 24, 25 . This would intuitively suggest a role for EndoS in evasion of adaptive immunity 70 through perturbation of protective IgG responses. However, studies on the influence of 71 EndoS on GAS pathogenesis have so far been few and inconclusive. They were unable to 72 demonstrate under which conditions EndoS is expressed and active and had to rely on 73 overexpression or addition of recombinant enzyme to manifest a virulence phenotype 25, 26 . 74
These efforts at elucidating the contribution of EndoS to GAS virulence have been hampered 75 by the difficulty of finding relevant model systems and the lack of a sensitive analytical 76 approach to quantify EndoS activity in complex systems 25, 26 . 77
We therefore wanted to take a different approach by first characterizing the effect of EndoS 78 on the hosts IgG glycosylation in vivo during the course of natural GAS infections in human 79 patients and then use these results to set up relevant model system able to show how EndoS 80 affects the hosts IgG response and how this contributes to GAS virulence. This necessitates 81 an assay that is robust, specific, and sensitive enough to be able to quantify the glycosylation 82 state of IgG in complex patient samples. We chose to employ selected reaction monitoring 83 (SRM), a targeted mass spectrometry approach that is uniquely suitable for this type of 84 analysis as it allows for the quantification of predefined target molecules (such as the EndoS 85 reaction products) directly from highly complex samples. SRM is based on precursor peptide 86 ion selection, fragmentation through collision, and detection of selected peptide fragment 87 ions in a triple quadrupole mass spectrometer. Precursor/fragment pairs, so called transitions, 88
are chosen that are unique to the molecule to be detected (i.e. the EndoS reaction products) 89 and data is only acquired for these defined targets (for a review see Picotti et al. 27 ). In 90 previous studies, proteins with concentrations as low as 300 ng/ml have been reliably 91 quantified out of crude human plasma preparations 28, 29 and SRM has also been used 92 successfully for quantification of the different glycan structures on IgG directly from serum 93 samples 30 . 94
We employed SRM-MS to quantitatively assess the EndoS-mediated IgG glycan hydrolysis 95 in samples from natural GAS infections in humans. We used these findings to set up relevant 96 in vitro assays and animal models in order to demonstrate the importance of EndoS-mediated 97 antibody modification in evasion of adaptive immunity and therefore GAS virulence. 98 . These methods lack sensitivity, specificity and/or 106 are ill suited for analysis of complex material. We therefore developed an SRM mass 107 spectrometry method to specifically quantify the amount of glycan-hydrolyzed IgGs (IgGGH). 108
Results
99
As EndoS cleaves within the chitobiose core of the IgG N-glycan (Fig. 1a) have the same precursor mass, we defined transitions that are in common and quantified both 118 peptides together. To assess total IgG levels, previously developed SRM assays for 119 quantification of each IgG subclass 37 were included. All the transitions are listed in Table S2 . 120
To determine the absolute amounts of IgG and IgGGH, we synthesized heavy-isotope labeled 121 standard peptides corresponding to the peptides we analyzed, which could be spiked into the 122 samples to act as internal standards (Fig. 1b) . The method was calibrated using a defined 123 human standard serum (Fig. S1&2 , Table S3 ) and validated by analyzing a set of human 124 blood plasma samples with defined amounts of IgGGH. For method comparison, the same 125 samples were also analyzed by SDS-PAGE and Lens culinaris agglutinin (LCA) lectin blot 126 (Fig. 1cd) . The SRM method exhibited better precision and accuracy as well as a much lower 127 detection limit. Especially for samples where the IgGGH content was low, as might be 128 expected in clinical samples, the SRM method outperformed the SDS-PAGE assay. This 129 together with low sample requirements, a large dynamic range and high analytical precision 130 (Fig. S1, S2 ) made this method highly suitable for the analysis of complex patient materials. 131
With this, method development was complete and we could start measuring EndoS activity 132 during GAS infections in vivo. 133
IGG GLYCANS ARE HYDROLYZED DURING GAS TONSILLITIS 134
Tonsillitis is the most common form of GAS infection and is characterized by throat pain, 135 fever, tonsillar exudates and cervical lymph node adenopathy 1 . To study the effects of EndoS 136 on patient IgGs during such an infection, we obtained 59 throat swab samples from a total of 137 54 patients who sought medical attention for a sore throat (Fig. 2a) . 26 of these were 138 diagnosed with GAS tonsillitis by rapid strep test and/or throat culture and were prescribed 139 oral antibiotics. The other 28 patients exhibited a negative strep test and throat culture; 140 therefore the infection was suspected to be viral and left untreated. 5 of the patients 141 diagnosed with GAS tonsillitis were willing to return after antibiotic treatment and an 142 additional throat swab was collected for each of these (Fig. 2a)  143 We used SRM mass spectrometry to quantitatively analyze the levels of IgGs as well as their 144 glycosylation status in these throat swab samples. We observed no difference between GAS-145 positive and GAS-negative patients in total IgG content or in the distribution of the four IgG 146 subclasses (data not shown). However, the percentage of glycan-hydrolyzed IgGs was 147 significantly higher in the GAS tonsillitis group, with glycan hydrolysis approaching 80% in 148 one case (Fig. 2b, left panel) . This was no longer detectable in any of the samples taken after 149 antibiotic treatment (Fig. 2b, right panel) . Furthermore, IgG glycan hydrolysis could be 150 correlated to the grade of throat pain and the general malaise experienced by the patients as 151 well as their Centor scores (a clinical scoring system aimed at distinguishing GAS tonsillitis 152 from viral infections 38 ) (Fig. 2c) . Taken together, these results suggest that EndoS is 153 expressed and active during acute GAS tonsillitis, but its effects quickly disappear upon 154 therapeutic intervention. 155
IGG ANTIBODIES ARE DEGLYCOSYLATED SYSTEMICALLY DURING GAS INDUCED SEPSIS 156
Sepsis is a state of systemic inflammation in response to an infection and the worst case 157 scenario in GAS infections 1 . To address the effect of EndoS on patient IgG antibodies during 158 invasive GAS infection leading to sepsis, we collected blood plasma from 32 patients 159 suffering from sepsis of various degrees of severity as well as 12 healthy volunteers. 18 160 patients had confirmed GAS infections whereas the other 14 suffered from various other 161 bacterial infections (Fig. 3a, table S5 ). All the sepsis patients were ranked according to the 162 degree of severity of their condition (sepsis, severe sepsis or septic shock). We used our SRM 163 method to determine IgG levels and glycosylation state in blood plasma (Fig. 3b, table S5 ). 164
The total IgG levels were not significantly different between the groups (Fig. 3b) and no 165 appreciable amounts of glycan-hydrolyzed IgG could be detected in any of the plasma 166 samples from the control groups (healthy or non-GAS sepsis). The same was true for milder 167 cases of GAS induced sepsis. However, the plasma of 5 out of 6 GAS patients suffering from 168 septic shock contained significantly increased amounts of IgGGH (up to 1 mg/ml in the most 169 severe case) (Fig. 3b) . 170
As we observed large differences in IgG glycan hydrolysis, even among the septic shock 171 patients, we hypothesized that differential expression of EndoS among the different GAS 172 strains infecting these patients could account for part of the observed variance. We were able 173 to obtain 6 GAS isolates from the blood cultures of these patients and analyzed the ability of 174 these strains to secrete EndoS into the culture medium in vitro. 3 isolates from severe sepsis 175 patients and 3 from septic shock patients ( SpeB is a secreted GAS virulence factor and has been shown to cleave the EndoS enzyme 39 . 185 Strikingly, SpeB is absent from the culture supernatant of the GAS isolate from patient 3 186 (with the highest degree of plasma IgG glycan hydrolysis, Fig. 3b ) and consequently EndoS 187 is largely intact. 188
The IgG glycan hydrolysis we observed in plasma reflects a systemic modification of IgG, 189 which, due to the abundance of the antibody in circulation, necessitates large amounts of IgG 190 to be deglycosylated to reach detectable levels. Locally, at site of infection, the effects of 191 EndoS on the IgG pool are likely to be much more pronounced. To test this, we obtained 192 wound swabs from the infected tissue taken during surgery from two of the sepsis patients 193 suffering from necrotizing fasciitis (patients 1 & 2). We analyzed them by SRM mass 194 spectrometry to determine the degree of IgG glycan hydrolysis and compared the results to 195 those previously obtained from analysis of plasma samples (Fig. 3d) . The samples originated 196 from two of the patients whose GAS isolates we have analyzed for EndoS expression in vitro 197 (Fig. 3c , patients 1 & 2). One isolate did not secrete any detectable amounts (Fig. 3c, patient  198 1) whereas the other one exhibited high EndoS expression (Fig. 3c, patient 2) . Accordingly, 199 two very different patterns of IgG glycan hydrolysis could be observed in these patients (Fig  200   3d ). The first patient showed no detectable IgG glycan hydrolysis in plasma and only a minor 201 amount in the wound swab sample. The second patient on the other hand exhibited moderate 202
IgG glycan hydrolysis in plasma (~0.7 % hydrolyzed) and the amount of IgGGH was 203 considerably higher in the wound swab sample from the same day (~30% hydrolyzed). This 204 was no longer detectable in a sample from the same site that was taken during a second 205 surgery the day after. 206
As we observed that local IgG glycan hydrolysis was transient, we wanted to determine how 207 long-lasting the EndoS-mediated perturbation of the systemic IgG pool was. To this end we 208 obtained further plasma samples taken throughout the treatment and recovery periods (until 209 12 days after admission) from the patient exhibiting the highest amount of IgGGH in plasma 210 (Fig. 3b, patient 3 ). Shortly after admission (time point 2h), the patient presented with very 211 low total IgG levels (3.3 mg/ml) and a high degree of IgG glycan hydrolysis (1 mg/ml). The 212 patient was given intravenous immunoglobulin (IVIG) treatment, upon which the total IgG 213 levels quickly normalized but the concentration of IgGGH stayed high throughout the 214 analyzed time interval and was still around 0.5 mg/ml at the 12 days end point (Fig. 3e) . 215
Taken together, these results show that EndoS is expressed and active during acute GAS 216 infection in vivo. It is able to hydrolyze the glycans from a considerable portion of the IgG 217 pool locally at the site of infection (both in tonsillitis and necrotizing fasciitis) as well as 218 systemically in the most severe cases of GAS sepsis. This points towards an important role 219
for EndoS in evasion of the immune defenses by perturbation of the hosts IgG response. 220
ENDOS IS EXPRESSED DURING GROWTH IN SALIVA AND PROTECTS GAS FROM PHAGOCYTIC 221 KILLING 222
While we were able to show that substantial IgG glycan hydrolysis takes place during GAS 223 infections, the functional consequences of this process for GAS pathogenesis remained 224 unclear and needed to be studied using appropriate model systems. As EndoS activity was 225 measureable in the majority of samples from GAS tonsillitis patients, we attempted to set up 226 a simplified in vitro model reminiscent of the conditions GAS encounters on an inflamed 227 tonsil during such an infection. When GAS colonizes the throat it would encounter saliva, an 228 increasing amount of plasma proteins as inflammation leads to vascular leakage 37 and finally 229 phagocytic immune cells trying to eradicate the bacteria. To approximate these conditions, 230 we grew GAS strains 5448 and AP1 as well as their respective isogenic ndoS mutants in 231 sterile-filtered saliva supplemented with 5% serum and tested if EndoS would be expressed 232 and active by SDS-PAGE. Based on electrophoretic mobility and/or LCA reactivity, both 233 wild type strains but neither of the mutants were able to fully deglycosylate the IgG pool 234 under these conditions ( EndoS reversed the phenotype. However, increased susceptibility to phagocytic killing was 245 only observed when the assay was performed in the presence of serum containing GAS-246 specific IgGs (as determined by measuring the IgG response to streptococcal M1 protein by 247 ELISA (Fig. S5) ). In the absence of specific IgGs both mutant and wild type exhibited similar 248 resistance to phagocytic killing. This indicates that EndoS confers increased resistance by 249 neutralizing specific IgGs directed towards the pathogen and prevents them from mediating 250
phagocytosis. 251 ENDOS MUTANT GAS ARE LESS VIRULENT IN A MOUSE MODEL OF INVASIVE GAS INFECTION 252
In order to study the role of EndoS in neutralization of GAS-specific IgGs in more detail and 253 determine its contribution to the outcome of streptococcal infection, we established a mouse 254 model. As IdeS has no discernible activity on relevant subclasses of murine IgG (IgG1 and 255 IgG2b) 40 we were able to use the more mouse-virulent strain AP1 for these experiments 256 without confounding the results. Wild type and ndoS mutant 34 GAS were used to infect 257 C57BL/6J mice subcutaneously and both local (skin) and systemic (plasma, spleen) samples 258 were taken at 48h post infection to determine bacterial loads as well as IgG glycan hydrolysis 259 by SRM mass spectrometry (Fig. 5a ). An assay analogous to the one for human IgGs was 260 developed to quantify murine IgG1 levels and its glycosylation status (Fig. S5) . As EndoS 261 does not exhibit any murine IgG subclass specificity 41 , this can be used as an indicator for 262 overall IgG glycan hydrolysis. When mice were infected with a wild type GAS strain, IgG1 263 was almost completely deglycosylated locally and around 30% glycan hydrolysis was 264 observed systemically (Fig. 5b, S8 ). The animals exhibited a heterogeneous response to 265 infection, with greatly varying degrees of severity observed. Consequently the measured 266 levels of IgG glycan hydrolysis also showed a large variance. We therefore tried to correlate 267
IgG glycan hydrolysis and bacterial load in the skin samples and found almost perfect 268 correlation (Fig. S5 ). Mice infected with the ndoS mutant developed local and systemic signs 269 of infection to a similar degree but showed no detectable IgG glycan hydrolysis (Fig. 5b,  270 
S7,8). This indicates that EndoS is expressed and active during such an infection but does not 271
confer any selective advantages under these naïve conditions. 272
As EndoS targets the adaptive immune response, its functional role during GAS infection is 273 most appropriately studied in the context of adaptive immunity. We therefore immunized 274 mice prior to infection through two injections with purified streptococcal M1 protein 275 combined with adjuvant. After an IgG response to M1 was confirmed, the mice were infected 276 subcutaneously and survival was monitored for 5 days (Fig. 5c ). This immunization protocol 277 lead to a complete protection at an infectious dose of 2.5×10 5 cfu which could be overcome 278 by increasing the dose to 2×10 7 cfu (Fig. S9) . The majority of mice infected with wild type 279 bacteria at that dose succumbed to the infection within 2-3 days. On the other hand, more 280 than 90% of the mice infected with ndoS mutant bacteria survived the infection with only 281 milder symptoms (Fig 5d, left) . This profound difference in susceptibility to infection 282 between wild-type and mutant could not be observed in animals that were mock immunized 283 by injection of adjuvant only, where both groups showed a similarly high mortality (>90%, 284 We here present the first evidence of a pathogen exploiting this regulatory mechanism by 295 specifically altering IgG Fc glycosylation in vivo during the clinical course of an infection. 296
By implementing a targeted proteomics approach based on SRM-MS we were able to study 297 the effects of EndoS on IgG antibodies during natural infections in human patients. Using 298 SRM we were able to detect and absolutely quantify glycan-hydrolyzed IgGs in a subclass 299 specific manner directly from a variety of very complex patient samples. With only minimal 300 amounts of sample required and detection limits below 0.5 ng, this method is far superior to 301 any other techniques used to measure IgG glycan hydrolysis to date. With this, we were able 302 to quantitatively address the effects of EndoS on a patient IgG population during 303 streptococcal infections. While a slight preference of EndoS towards IgG1 42 has been 304 reported, we did not observe any subclass specificity in any of the patient samples (Table  305 S4,5). Locally, at the site of infection, the degree of IgG glycan hydrolysis was generally high 306 (up to nearly complete hydrolysis) but the effects were only transient, disappearing quickly 307 upon therapeutic intervention. This was true both for mild infections (tonsillitis) as well as 308 severe, invasive infections (necrotizing fasciitis). This indicates that at site of infection, IgG 309 is turned over quickly and constantly replenished from the circulation and IgG glycan 310 hydrolysis is only detectable as long as bacterial load is high and EndoS is continuously 311 secreted. Due to the much larger amount of IgG in circulation as compared to the infected 312 tissue and the increased dilution of the enzyme further away from the site of infection, effects 313 on the systemic IgG pool in circulation were much harder to detect and therefore rarer. Only 314 in the most severe cases of invasive infections (septic shock), could glycan hydrolysis be 315 observed systemically. This systemic IgG glycan hydrolysis was long lasting with 316 approximately half of the glycan-hydrolyzed IgGs still present after 12 days. A similarly slow 317 recovery of IgG glycosylation to normal levels was also observed when rabbits or mice were 318 injected with recombinant EndoS as an experimental treatment of autoimmunity 31, 43 . 319
In both of our patient sets, only a portion of the patient samples showed detectable levels of 320 IgGGH (58% of tonsillitis patients locally and 28% of sepsis patients systemically). In part, 321 this might be due to some GAS isolates expressing only very low levels of EndoS (Fig. 3c) . 322
In vivo glycan hydrolysis was not associated with covRS mutation or any specific emm-type. 323
Indeed we detected it in infections with at least different 8 different emm-types (Table S4,5) . 324
All publicly available GAS genome sequences contain an ndoS or an ndoS-like gene 44 , but 325 expression of the EndoS protein differs greatly between different GAS isolates. However, the 326 fact that IgG glycan hydrolysis correlates to disease severity both in tonsillitis and invasive 327 disease indicates that we -due to analytical limitations -might not be able to detect EndoS-328 mediated IgG glycan hydrolysis in samples from patients suffering from less severe 329
infections. This is true especially for the GAS sepsis patient samples. Apart from two 330 exceptions, we were only able to study IgG in blood plasma and therefore were unable to 331 address potential perturbations of the local IgG pool at site of infection in more detail. Indeed 332 among the sickest patients in each cohort the percentage of samples with detectable IgGGH 333 was considerably higher. 5 out of 6 GAS septic shock patients (83%) exhibited measureable 334 systemic IgG glycan hydrolysis and among the sickest half of the tonsillitis patients (based on 335 estimation of general malaise) glycan hydrolysis of the local IgG pool was detectable in all 336 but one patient (92% total). While studying the activity of EndoS during GAS tonsillitis, we 337 also observed a considerable amount of IgG glycan hydrolysis in some of our control samples. 338
We speculate that this was due to enzymatic activities of the oral micro flora, especially oral 339 streptococci which are known to express a large number of glycoside hydrolases 45 . This is 340 supported by the fact that IgG glycan hydrolysis was not detectable in any of the samples we 341 took after antibiotic treatment. 342
While we were able to show that IgG glycan hydrolysis takes place during GAS infection in 343 vivo, the functional consequences of this process could not be deduced directly from the 344 patient data. Removal of the Fc glycan by EndoS has previously been shown to impair both 345
Fc receptor interaction and complement activation in vitro 20, 25 We used our characterization of IgG glycan hydrolysis in vivo to set up relevant model 361 systems to address the contribution of EndoS to GAS pathogenesis. Based on our findings on 362
IgG glycan hydrolysis during GAS tonsillitis, we were able to approximate the conditions 363 GAS encounters on an inflamed tonsil using human saliva and serum. This prompted wild 364 type bacteria to secrete enough EndoS to completely deglycosylate the IgGs present and 365 neutralize the contribution of GAS-specific IgGs to phagocytic killing by human 366 macrophages or neutrophils in vitro. ndoS mutant bacteria on the other hand were unable to 367 cleave the glycans from IgG and consequently exhibited a higher susceptibility to phagocytic 368 killing. This phenotype could be reversed by externally adding recombinant EndoS. These 369 results, together with the fact that the ndoS mutation had no phenotype in the absence of 370 GAS-specific IgGs indicates that the observed phenotype is due to deglycosylation of the 371 GAS-specific IgGs which in turn impairs their ability to mediate phagocytic killing. There 372 seems to be no general attenuation of the ndoS mutant, nor any benefits in glycan hydrolysis 373 of non-specific IgGs. 374
An animal model of local skin infection leading to invasive infection showed very similar 375 dynamics. Mice infected with ndoS mutant bacteria exhibited no IgG glycan hydrolysis and 376 were significantly less likely to die from the infection than mice infected with wild type GAS. 377
This difference was however only clearly evident in the context of adaptive immunity (i.e. in 378 animals that had been immunized against GAS prior to infection). In agreement with the 379 results from the phagocytosis assays and previous studies 26 , naïve mice showed a very similar 380 susceptibility towards both wild type and ndoS mutant bacteria; with no significant 381 differences in survival, weight loss or bacterial load in the skin (Fig. 5, Fig. S7 ). Only the 382 bacterial burden in the spleen was slightly decreased in mice infected with ndoS mutant 383 bacteria (Fig. S7) . Its mode of action is thought to involve neutralization of bacterial 388 superantigens and inhibition of pro-inflammatory signaling [57] [58] [59] . Our data points to another 389 reason why IVIG treatment could improve the outcome of severe streptococcal infections. 390
EndoS-mediated glycan hydrolysis inactivates IgGs and as shown in this study, such antibody 391 modifications can be systemic, long lasting and affect a considerable fraction of the patient's 392 total IgG pool. GAS can lower functional IgG levels even further through secretion of the 393
IgG protease IdeS 11,37 . In such cases, IVIG in concert with antimicrobial therapy could help 394 to quickly normalize the level of functional IgG in circulation. We observed such an effect in 395 one patient (Fig. 3e, patient 3) . 396
Despite an abundance of anti-GAS IgGs in the serum of most people 4-7 , protective immunity 397 towards the pathogen does not ensue. Furthermore, development of effective GAS vaccines 398 has proven challenging. Herein we present a possible mechanism to explain why anti-GAS 399
IgGs often confer such poor protection: GAS is able to effectively neutralize the contribution 400 of IgG to host defense through specific degradation of the IgG antibodies. We have 401 demonstrated the dynamics of IgG glycan hydrolysis by EndoS in this study and a recent 402 study has also shown significant levels of IdeS-mediated IgG proteolysis during GAS 403 infections in vivo 37 . This makes GAS a very proficient evader of IgG-mediated immunity, a 404 fact that has implications for the treatment of severe GAS infections and has to be taken into 405 account in future research into the immune response to GAS as well as in the continuing 406 efforts at development of an effective vaccine against the pathogen. Finally, immune evasion 407 through modification of IgG glycosylation might not be restricted to GAS 
Materials and Methods
PATIENT SAMPLES 416
Tonsillar swabs (n = 54, ESwab Liquid Amies) were obtained from patients (>8 years old) 417 seeking clinical care because of a sore throat at the primary healthcare clinics at 418
Laurentiikliniken and Skåne University Hospital (SUS) both in Lund, Sweden. GAS 419 tonsillitis was diagnosed by rapid strep test (antigen detection) and routine bacterial culturing. 420
A follow-up tonsillar swab sample (3-5 days post) was taken from a subset of patients (n=5) 421 treated with antibiotics (Table S4 ). Wound swabs from the local infection site of patients 422 clinically diagnosed with GAS sepsis and necrotizing fasciitis were obtained from SUS, Lund 423 Sweden (n=4) during surgical intensive care (Table S5) 
Considerations' section below). 429 SAMPLE PREPARATION FOR MASS SPECTROMETRY 430
Proteins from the swab samples were extracted and homogenized in water using a bead-431 beater (Fastprep-96, MP-Biomedicals). 0.625 µl plasma or 50 µg of protein from swabs or 432 skin homogenates were prepared for MS analysis using the SmartDigest Kit (Thermo 433 Scientific). Samples were denatured at 90°C followed by digestion for 3.5 hours at 70°C. The 434 peptides were reduced using 50 mM TCEP, alkylated with 100 mM iodoacetamide and 435 finally purified using SOLAµ HRP plates (Thermo Scientific). The peptide samples were 436 dried in a vacuum centrifuge and dissolved in 100 µl 50 mM sodium acetate buffer (pH 5) 437 containing 50 mU Thermatoga maritima α-fucosidase (Megazymes). After incubation at 438 70°C for 14 h, the samples were purified a second time on SOLAµ HRP plates and dried in a 439 vacuum centrifuge. 440
SRM MASS SPECTROMETRY 441
Peptide samples were dissolved in 2%ACN, 0.2% FA and AQUA peptides (Thermo 442
HeavyPeptide QuantPro, table S3) were spiked in. The amount of peptide standards was 443 adjusted so that the ratio of light to heavy signal falls within the interval of 0.1 to 10. Sample 444 corresponding to 1 µg of protein were analyzed by SRM mass spectrometry using a TSQ 445
Vantage triple quadrupole mass spectrometer coupled to an Easy-nLC II system (both 446 Thermo Scientific) equipped with a PicoChip column (PCH7515-105H354-FS25, New 447 Objective). Data was acquired with a spray voltage of 1500V, 0.7 FWHM on both 448 quadrupoles and a dwell time of 10ms. Assays for all the non-glycopeptides were obtained 449 from published studies 37,64 while glycopeptide assays were developed as described here 65 . 450
Assay set-up, empirical collision energy optimization as well as data analysis was done using 451 by the manufacturer, we could also use this dataset to calibrate the quantification and correct 472 for incomplete digestion and sample loss during preparation. For each data point above LOD 473 and with a light to heavy between 0.1 and 10 conversion factors were determined by dividing 474 the known IgG subclass concentrations with the measured light to heavy ratios. These 475 conversion factors were averaged (table S3) and are used to determine absolute amounts from 476 measured light to heavy ratios in all further experiments with human samples. The same 477 procedure was followed when the assay for murine IgG1 was developed. The standard 478 sample there was a monoclonal mouse IgG1 (MA-69, Biolegend, San Diego, USA) that was 479 treated with recombinant EndoS and spiked into human plasma as a background proteome. 480
SDS-PAGE AND LECTIN BLOT 481
IgG was purified using Protein G (Ab SpinTrap, GE Healthcare). Samples were separated on 482 SDS-PAGE (Mini-protean TGX stainfree gels, 4-15% acrylamide, BioRad), imaged using a 483
ChemiDoc MP imaging system (BioRad) and transferred to low fluorescent PVDF 484 membranes using the Transblot Turbo kit (BioRad). Membranes were blocked for 1h in lectin 485 buffer (10 mM HEPES pH7.5, 150 mM NaCl, 0.01 mM MnCl2, 0.1 mM CaCl2, 0.1% (v/v) 486 tween 20) followed by incubation with 5 µg/ml fluorescein-labeled LCA lectin (Vector 487 laboratories). After extensive washing in lectin buffer, the membranes were imaged using a 488 EndoS or SpeB rabbit antiserum 12,68 another wash and incubation with a secondary antibody 500 (goat anti-rabbit HRP-conjugated antibody, BioRad). The membranes were developed using 501 Clarity Western ECL substrate (BioRad) and visualized with a ChemiDoc MP Imager (Bio-502 Rad, USA). 503
ANALYSIS OF EMM AND COVRS SEQUENCES 504
emm sequences of the GAS clinical isolates were analyzed according to protocols published 505 by the CDC and compared to a database of known emm sequences using the tool on the CDC 506 website (https://www2a.cdc.gov/ncidod/biotech/strepblast.asp). The covRS operon was 507 sequenced as previously described 69 and compared to published sequences of the same 508 serotype. 509
IN VITRO TONSILLITIS MODEL 510
Preparation of saliva: Saliva from healthy volunteers was collected in the morning after 511 extensive brushing of the teeth. The saliva was centrifuged (20 min, 20000 g), sterile filtered 512 (Steriflip GP 0.22 µm, Milipore) and either used directly or kept at -20°C until use. 513
Preparation of polymorphonuclear leukocytes (PMNs): 20 ml blood was collected into 514 EDTA blood collection tubes (BD Bioscience) and the PMNs were isolated using 515
PolyMorphPrep (Axis-shield) according to manufacturers recommendations. After counting, 516 the cells were diluted into RPMI medium and seeded at 50000 cells/well into a 96-well plate. 517
Preparation of monocyte derived macrophages (MDMs): 518
Peripheral blood mononuclear cells (PBMCs) were isolated from leukocytes of healthy 519 anonymous donors provided by the Lund University Hospital. Red blood cells were removed 520 by centrifugation on Lymphoprep (Fresenius Norge As, Oslo, Norway) and recovered 521
PBMCs were washed to remove platelets. Monocytes were isolated using a magnetic cell 522 separation system with anti-CD14 mAb-coated microbeads (Miltenyi Biotec). CD14-positive 523 monocytes were seeded into 12 well plates at 5 × 10 5 cells/well and differentiated into 524 macrophages by culture in complete RPMI 1640 medium (Gibco) supplemented with 10% 525 heat-inactivated human AB+ serum, 50 nM β-mercaptoethanol (GIBCO), Penicillin-526 Streptomycin (Sigma) and 40 ng/ml M-CSF (Peprotech) at 37°C under a humidified 5% CO2 527 atmosphere for 6 days. Medium was replaced on day 2 and on day 4, when cells were washed 528 with PBS and the medium was replaced with antibiotic-fee medium. The cells were further 529 incubated until day 6 when the infection experiments took place. 530
Killing assays: GAS 5448 and an isogenic ndoS mutant 26 were grown overnight in THY 531 medium at 37°C, 5% CO2, diluted 1:10 into fresh medium and let grow to mid-log phase (OD 532 = 0.4). Cultures were diluted 1:50 into 1 ml of saliva, incubated for 2h at 37°C, 5% CO2 and 533 diluted again (1:20) into 1 ml fresh saliva (supplemented with 5% serum and 0.5 µg/ml 534 recombinant EndoS where suitable). After 20h at 37°C, 5% CO2 the bacteria were diluted 535 1:10 into RPMI medium and used to infect PMNs or MDMs at an MOI of 2. After 30min (for 536 PMNs) or 2 h (for MDMs) incubation at 37°C, 5% CO2 the cells were lysed using ddH2O 537 (for PMNs) or 0.025% Triton X-100 (for MDMs) and the number of surviving bacteria was 538 determined by plating on THY agar plates. 539
ANALYSIS OF ENDOS EXPRESSION IN VITRO 540
AP1, the ndoS mutant and the GAS clinical isolates were grown in C-medium (37°C and 5% 541 CO2) overnight and normalized to the same OD620 using fresh C-medium. Bacteria were 542 pelleted by centrifugation and the supernatants filtered (Millex-GP filter unit 0.22µm, 543 Millipore). Proteins were precipitated from the supernatants with 5% TCA (trichloroacetic 544 acid) and analyzed by SDS-PAGE under reducing conditions. Proteins were transferred to 545 PVDF-membranes using the Trans-Blot Turbo kit (Bio-Rad Laboratories) according to 546 manufacturer's instructions. Membranes were blocked with 5% (w/v) blotting-grade blocker 547 (Bio-Rad Laboratories) in PBST, followed by incubation with EndoS 34 or SpeB 68 antiserum 548
The membranes were washed followed by incubation with a secondary antibody (goat anti-549 rabbit HRP-conjugated antibody, BioRad). The membranes were developed using Clarity 550
Western ECL substrate (BioRad) and visualized with a ChemiDoc MP Imager (Bio-Rad, 551 USA). 552
MOUSE INFECTIONS: 553
Acute infection model of GAS in naïve C57BL/6J mice GAS AP1 and ndoS mutant (Table S1) All statistical analyses were preformed using GraphPad Prism 7. Phagocytic killing assays 577 were analyzed using one-way ANOVA followed by Tukey´s multiple comparison test. IgG 578 hydrolysis data was analyzed using a Mann-Whitney test or a Kruskal-Wallis test in 579 combination with Dunn´s multiple comparison test (when more than two datasets were 580 compared). Correlation was determined according to Spearman and survival data was 581 analyzed using a Mantle-Cox test. The whiskers reach from the smallest to the largest data point, all of which are marked as 838 circles. Glycan hydrolysis of the individual subclasses is shown in table S4. The 839 glycopeptides from IgG3 and IgG4 could not be measured in these samples due to interfering 840 background and were omitted from this analysis. Data was analyzed using a Mann-Whitney 841 test (Table S6 ) (ns: p>0.05, **: p<0.01). 842
c) The tonsillitis patients were asked to grade their a general malaise (left) and throat pain 843 (middle) on a scale from 0-10 and the centor score 38 (right) was determined. These 844 parameters were correlated to the IgG glycan hydrolysis measured in tonsillar swabs using 845 SRM-MS. Correlation was analyzed according to Spearman (Table S7) . 
